**Supplementary table 2. Baseline demographic and clinical characteristics of the patients who are candidates for initiation of dapagliflozin treatment at index hospitalization.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All patients**  **N=4470** | **HFrEF**  **N=1199** | **HFpEF**  **N=3271** | **P** |
| **Biodemographic data** | | | | |
| Age (years) (mean (SD)) | 79.9 (8,6) | 77.4 (9.9) | 80.8 (7.9) | < 0.001 |
| Sex female | 53.7% | 36.4% | 60.1 | < 0.001 |
| Charlson index, points (SD) | 3.0 (2.4) | 3.3 (2.5) | 2.9 (2.4) | < 0.001 |
| Barthel index, points (SD) | 82.7 (22.3) | 86.5 (19.7) | 81.1 (23.1) | < 0.001 |
| Pfeiffer index, points (SD) | 1.5 (1.6) | 1.6 (1.7) | 1.5 (1.5) | 0.4 |
| **Physical examination** | | | | |
| BMI (kg/m2) (mean (SD)) | 29.2 (6.3) | 28.0 (7.8) | 29.7 (6.5) | < 0.001 |
| Systolic blood pressure | 137.1 (26.2) | 132.2 (25.2) | 139.2 (26.5) | < 0.001 |
| Diastolic blood pressure | 74.7 (15.5) | 75.3 (15.0) | 74.7 (15.8) | 0.1 |
| Heart rate | 86.2 (22.3) | 87.3 (22.7) | 86.1 (22.3) | 0.04 |
| **HF data** | | | | |
| HF etiology  Ischemic (N=1169)  Valvulopathy (782)  Hypertensive (1810)  Others (N=194)  Non classified (N=315) | 26.0%  17.4%  40.3%  4.3%  7.0% | 47.1%  10.2%  17.2%  4.3%  10.7% | 18.2%  19.8%  48.1%  7.1%  6.8% | < 0.001 |
| NYHA functional class  II  III  IV | 60.5%  36.6%  3.0% | 55.1%  42.2%  2.7% | 62.2%  34.6%  3.1% | < 0.001 |
| LVEF, % (SD) | 51.8 (15.5) | 30.9 (7.2) | 59.3 (9.7) | < 0.001 |
| **Cardiovascular risk factors** | | | | |
| Hypertension | 87.2% | 82.8% | 88.9% | < 0.001 |
| Dyslipidaemia | 51.9% | 54.7% | 50.4% | 0.01 |
| Diabetes mellitus | 46.8% | 48.0% | 46.4% | 0.2 |
| Obesity | 38.2% | 28.1% | 41.8% | <0.001 |
| Current smoker | 5.2% | 8.7% | 3.9% | < 0.001 |
| **Vascular disease** | | | | |
| Coronary artery disease | 24.0% | 37.5% | 19.0% | < 0.001 |
| Cerebrovascular disease | 13.4% | 13.8% | 9.4% | 0.3 |
| Peripheral arterial disease | 10.3% | 13.3% | 13.2% | < 0.001 |
| **Other comorbidities** | | | | |
| Atrial fibrillation | 54.5% | 42.6% | 58.7% | < 0.001 |
| Chronic kidney disease | 55.2% | 57.9% | 54.4% | 0.02 |
| COPD | 24.1% | 26.7% | 23.6% | 0.02 |
| Cancer | 11.8% | 12.5% | 11.4% | 0.2 |
| Dementia | 5.4% | 5.7% | 5.4% | 0.3 |
| **Laboratory parameters** | | | | |
| Hemoglobin, mg/dL (SD) | 12.1 (2.0) | 12.5 (2.0) | 11.9 (1.9 | <0.001 |
| Glucose, mg/dL (SD) | 136.6 (62.3) | 138.5 (68.1) | 136.2 (60.7) | 0.3 |
| HbA1c, % (SD) | 6.9 (1.7) | 7.2 (2.6) | 6.8 (1.3) | < 0.01 |
| Creatinine, mg/dL (SD) | 1.2 (0.4) | 1.2 (0.4) | 1.2 (0.4) | <0.01 |
| Urea, mg/dL (SD) | 65.4 (31.3) | 65.7 (30.6) | 65.4 (31.7) | 0.7 |
| eGFR, ml/min/1.73 m2 (SD) | 61.1 (25.2) | 61.6 (25.9) | 60.8 (24.9) | 0.4 |
| Sodium, mmol/L (SD) | 138.7 (5.4) | 138.4 (5.6) | 138.8 (5.4) | 0.03 |
| Potassium, mmol/L (SD) | 4.3 (0.6) | 4.3 (0.6) | 4.3 (0.6) | 0.6 |
| Uric acid, mg/dL (SD) | 7.8 (2.4) | 7.9 (2.4) | 7.8 (2.4) | 0.1 |
| Total cholesterol, mg/dL (SD) | 145.9 (34.6) | 144.7 (34.4) | 143.7 (34.5) | 0.8 |
| Troponin I ng/mL (SD) | 1.2 (0.5) | 1.4 (0.6) | 1.1 (0.4) | < 0.01 |
| BNP\*, pg/mL (SD) | 1286 (2839) | 2043 (3946) | 907.8 (1969) | < 0.001 |
| NT-proBNP, pg/mL (SD) | 6472 (12906) | 8916 (9908) | 5680 (13849) | <0.001 |
| CA 125, U/mL (SD) | 85.0 (137.0) | 100.6 (142.0) | 80.8 (136.4) | 0.10 |
| **Outpatient treatment** | | | | |
| Loop diuretics | 75.1% | 74.9% | 75.6% | 0.4 |
| ACEi or ARB  ARNI | 64.1%  2.7% | 65.2%  8.0% | 63.5%  0.8% | 0.2  < 0.001 |
| Beta-blockers | 68.2% | 81.9% | 63.4% | < 0.001 |
| MRA | 24.5% | 38.3% | 19.6% | < 0.001 |

ACE: Angiotensin-converting enzyme; ARB: angiotensin receptor II blocker; ARNI: angiotensin receptor neprilysin inhibitor; BMI: body mass index; COPD: Chronic obstructive pulmonary disease; HF: Heart Failure; HFrEF: heart failure with reduced ejection fraction; HFpEF: heart failure with preserved ejection fraction; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor antagonists; NYHA: New York Heart Association; SD: standard deviation. \*intrahospital values. There were missing data/value for: BNP in 360 patients, Total cholesterol in 110, Uric acid in 1798, Troponin in 954, NT-proBNP in 1518, Ca 125 in 450, Glucose in 2839, HbA1c in 667.